Abstract: The invention relates to novel compounds useful as ligands of actinides and which meet general formula (I) hereinafter: where: R1 and R2?H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; R3, R4, R5 and R6?H; a C1 to C12 hydrocarbon group; a monocyclic aryl or aryl-(C1 to C6)alkyl group; a —NR7R8 or —NR7COR8 group where R7?H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group, whilst R8=a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; an —OR9 or —SR9 group where R9=a C1 to C12 hydrocarbon group, a monocyclic C6 aryl or aryl-(C1 to C6)alkyl group. A further subject of the invention is a method for synthesizing these compounds and the uses thereof.

Abstract: The invention relates to novel compounds which are useful as ligands of actinides, to the synthesis of these compounds and to their uses. These compounds fit the general formula (I) hereafter: wherein R1 and R2, either identical or different, represent H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl, benzyl, diphenyl or tolyl group; R3 represents H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl, tolyl or linear or branched C1-C12 alkoxy group; while R4 represents H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl or tolyl group. Field of applications: the processing of used nuclear fuels via a hydrometallurgical route.

Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, proteins encoded thereby, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, and methods for treating a cell using such nucleic acids or proteins.

Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, proteins encoded thereby, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, and methods for treating a cell using such nucleic acids or proteins.

Abstract: Antiperspirant water in oil emulsions can suffer from inferior sensory properties, including wetness and/or slow “dry-down” and/or stickiness, even when the composition contains a polyhydric humectant, a known class of skin moisturiser. A balance of sensory properties can be achieved by formation of a base composition in the form of a water in oil emulsion in which the oil phase, preferably comprising 20 to 55% of the base composition, contains at least threshold proportions of both a volatile silicone and a sensory modifying oil, particularly selected from dicaprylyl ether and dicaprylyl carbonate, the sensory modifying oil advantageously being present in a weight ratio to the polyhydric humectant of from 3:4 to 4:1. Such compositions are particularly suitable for mixture with a liquifiable propellant to form aerosol compositions.

Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom, methods for treating a cell using such nucleic acids, proteins or pharmaceutical compositions, and the use of such nucleic acids or proteins in formulating a pharmaceutical preparation.

Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom, methods for treating a cell using such nucleic acids, proteins or pharmaceutical compositions, and the use of such nucleic acids or proteins in formulating a pharmaceutical preparation.

Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom, methods for treating a cell using such nucleic acids, proteins or pharmaceutical compositions, and the use of such nucleic acids or proteins in formulating a pharmaceutical preparation.